- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07321821
Fermented Garlic Lettuce Powder and Cognitive Function in Adults With Mild Cognitive Impairment
January 8, 2026 updated by: Yong-il Shin, Pusan National University Yangsan Hospital
The Effect of Fermented Garlic Lettuce Powder on Cognitive Function in Adults With Mild Cognitive Impairment: An Investigator-Initiated, Randomized, Assessor-Blinded, Parallel-Group, Controlled, Single-Center Study
"This study aims to investigate the cognitive and psychological changes in adults with mild cognitive impairment (K-MoCA scores between 16 and 23) following daily consumption of fermented garlic lettuce powder for 2 months
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
60
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Gyeongsangnam-do
-
Yangsan, Gyeongsangnam-do, South Korea
- Pusan National University Yangsan Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Adults aged 19 years or older with K-MoCA scores between 16 and 23.
- Individuals with sufficient vision and hearing to participate in the study without difficulty.
- Participants who are currently taking medications or receiving treatments that may affect cognition and are able to maintain the same dosage and regimen throughout the study period.
- Individuals who voluntarily agree to participate in the study and provide written informed consent.
Exclusion Criteria:
- Individuals who have undergone vascular-related surgery within the past 6 months or gastrointestinal surgery that may affect absorption of the study product (excluding simple appendectomy or hernia repair).
- Individuals with a clinically significant history of hypersensitivity to medications or dietary supplements.
- Individuals with a history of alcohol or drug abuse.
- Individuals unable to communicate effectively.
- Individuals who have participated in more than two dietary supplement studies or clinical trials within the current year, or within the past 6 months.
- Individuals deemed unable to participate safely or effectively in the study by the investigator.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Fermented Garlic Lettuce Powder
Participants receive fermented garlic lettuce powder, administered orally as three tablets per day for 2 months (total of 180 tablets).
|
The Garlic Lettuce Fermented Powder tablets (intervention group) are taken 3 tablets daily for 2 months, totaling 180 tablets
|
|
Placebo Comparator: Placebo Tablet
Participants take 1 placebo tablet daily for 2 months, totaling 60 tablets
|
Participants take 1 placebo tablet daily for 2 months, totaling 60 tablets
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
K-MoCA
Time Frame: Assessments are performed at baseline and at 2 months.
|
The Korean version of the Montreal Cognitive Assessment (K-MoCA) is a cognitive screening tool with scores ranging from 0 to 30, with higher scores indicating better cognitive function.
The outcome measure is the change in K-MoCA score.
|
Assessments are performed at baseline and at 2 months.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
SVLT
Time Frame: Assessments are performed at baseline and at 2 months.
|
The Seoul Verbal Learning Test (SVLT) is a neuropsychological assessment tool used to evaluate verbal memory performance.
Scores range from 0 to 36, with higher scores indicating better memory function.
|
Assessments are performed at baseline and at 2 months.
|
|
KCWS
Time Frame: Assessments are performed at baseline and at 2 months.
|
The Korean Color-Word Stroop Test (KCWS) is a neuropsychological assessment used to evaluate executive function and cognitive control.
Performance is measured by the number of correct responses within 1- and 2-minute intervals, with higher scores indicating better cognitive function.
|
Assessments are performed at baseline and at 2 months.
|
|
RCFT
Time Frame: Assessments are performed at baseline and at 2 months.
|
The Rey Complex Figure Test (RCFT) is a neuropsychological assessment used to evaluate visuospatial constructional ability and visual memory.
Scores range from 0 to 36, with higher scores indicating better memory performance.
|
Assessments are performed at baseline and at 2 months.
|
|
DST
Time Frame: Assessments are performed at baseline and at 2 months.
|
The Digit Span Test (DST) is a neuropsychological assessment used to evaluate attention and working memory.
Scores range from 0 to 24, with higher scores indicating better concentration and attention.
|
Assessments are performed at baseline and at 2 months.
|
|
COWAT
Time Frame: Assessments are performed at baseline and at 2 months.
|
The Controlled Oral Word Association Test (COWAT) is a neuropsychological assessment used to evaluate verbal fluency and executive function.
Scores range from 0 to 27, with higher scores indicating better verbal fluency, executive function, attention, and problem-solving abilities.
|
Assessments are performed at baseline and at 2 months.
|
|
BDI
Time Frame: Assessments are performed at baseline and at 2 months.
|
The Beck Depression Inventory (BDI) is a self-report questionnaire used to assess the severity of depressive symptoms.
Each item is scored from 0 to 3, with total scores ranging from 0 to 63, where higher scores indicate more severe depressive symptoms.
|
Assessments are performed at baseline and at 2 months.
|
|
EQ-5D
Time Frame: Assessments are performed at baseline and at 2 months.
|
The EuroQol-5 Dimension (EQ-5D) is a standardized instrument for measuring health-related quality of life.
Scores range from 0 to 100, with lower scores indicating better perceived health status and higher scores reflecting more severe health problems.
|
Assessments are performed at baseline and at 2 months.
|
|
MFS
Time Frame: Assessments are performed at baseline and at 2 months.
|
The Multidimensional Fatigue Scale (MFS) is a self-report questionnaire used to assess fatigue across multiple dimensions.
Each dimension is rated from 0 to 20, with a total score ranging from 0 to 100.
Lower scores indicate less fatigue, while higher scores reflect more severe fatigue.
|
Assessments are performed at baseline and at 2 months.
|
|
PWI-SF
Time Frame: Assessments are performed at baseline and at 2 months.
|
The Psychological Well-Being Index-Short Form (PWI-SF) is a self-report questionnaire used to assess psychological well-being.
Each dimension is rated from 0 to 20, with total scores ranging from 0 to 54, where higher scores indicate better psychological well-being, life satisfaction, and emotional stability.
|
Assessments are performed at baseline and at 2 months.
|
|
LSEQ
Time Frame: Assessments are performed at baseline and at 2 months.
|
The Leeds Sleep Evaluation Questionnaire (LSEQ) is a self-report instrument used to assess subjective sleep quality.
Scores are based on a scale from 0 to 100, with higher scores indicating better sleep quality and lower scores reflecting greater sleep disturbance.
|
Assessments are performed at baseline and at 2 months.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 19, 2025
Primary Completion (Estimated)
January 21, 2026
Study Completion (Estimated)
January 21, 2026
Study Registration Dates
First Submitted
December 23, 2025
First Submitted That Met QC Criteria
December 23, 2025
First Posted (Estimated)
January 7, 2026
Study Record Updates
Last Update Posted (Estimated)
January 12, 2026
Last Update Submitted That Met QC Criteria
January 8, 2026
Last Verified
January 1, 2026
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 11-2024-061
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Mild Cognitive Impairment (MCI)
-
University of FloridaRecruitingMild Cognitive Impairment (MCI) | Mild Cognitive Impairment | MCIUnited States
-
High Point UniversityWake Forest University Health Sciences; Hebrew SeniorLifeRecruitingMild Cognitive Impairment (MCI)United States
-
Azienda Ospedaliera SS. Antonio e Biagio e Cesare...Dr. Schär AG / SPARecruitingMild Cognitive Impairment (MCI)Italy
-
Immunotec Inc.RecruitingMild Cognitive Impairment (MCI)Canada
-
Çankırı Karatekin UniversityCompletedMild Cognitive Impairment (MCI)Turkey (Türkiye)
-
University of AlbertaCompleted
-
Friedhelm HummelThe Novartis Foundation; Wyss Center for Bio and Neuroengineering; Clinique Romande... and other collaboratorsCompletedMild Cognitive Impairment (MCI)Switzerland
-
Meir Medical CenterTerminatedMild Cognitive Impairment (MCI)Israel
-
Indivi AGRecruitingMild Cognitive Impairment (MCI) | Mild Alzheimer DiseaseUnited States
-
Singapore General HospitalSingapore Health ServicesNot yet recruitingMild Cognitive Impairment (MCI) | Mild Cognitive Impairment
Clinical Trials on Garlic Lettuce Fermented Powder
-
Ain Shams UniversityCompletedInflammation | Hemodialysis | CKD | Endothelial DysfunctionEgypt
-
Hiroshima UniversityWakunaga Pharmaceutical Co., Ltd.CompletedHypertriglyceridemiasJapan
-
Chonbuk National University HospitalCompletedHyperlipidemiaKorea, Republic of
-
National Center for Complementary and Integrative...CompletedArteriosclerosis | Intracranial ArteriosclerosisUnited States
-
Chonbuk National University HospitalCompletedFatty Liver, NonalcoholicKorea, Republic of
-
Institute for Atherosclerosis Research, RussiaCompletedCarotid AtherosclerosisRussian Federation
-
Silliker, Inc.National Center for Complementary and Integrative Health (NCCIH)Unknown
-
Chonbuk National University HospitalCompletedObesityKorea, Republic of
-
Fred Hutchinson Cancer CenterNational Center for Complementary and Integrative Health (NCCIH)Completed